Streetbeat News

Products Services

META

TikTok and Instagram, owned by ByteDance and Meta Platforms Inc. (NASDAQ:META) respectively, continue to dominate as the world's most downloaded apps in September. Elon Musk's X and Mark Zuckerberg's Threads were notably absent from the rankings. X has seen a significant 18% drop in app downloads compared to last year, and its fortunes have plummeted to an alarming low, attracting only 10 million users between August and September.

Portfolio Pulse from Ananya Gairola

October 10, 2023 | 11:07 am

NVS

OLMA

Olema Oncology has expanded its collaboration agreement with Novartis, significantly increasing the size of the ongoing Phase 1/2 clinical study testing palazestrant in combination with ribociclib.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 11:06 am

PSTV

Plus Therapeutics, Inc. (PSTV) has completed dosing in Cohort 4 of the ReSPECT-LM Phase 1/2a clinical trial of rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases from solid tumors. The company has also completed the transfer of proprietary materials, protocols, and equipment from Biocept under the terms of the recently announced expanded agreement for CNSide.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 11:04 am

AKRO

Akero Therapeutics, Inc. (NASDAQ:AKRO) reported a 36-week analysis of its 96-week Phase 2b SYMMETRY study. The study evaluates the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH). The results showed a trend on fibrosis improvement and statistically significant results for NASH resolution, markers of liver injury and fibrosis, insulin sensitization and lip.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 11:03 am

BTAI

BioXcel Therapeutics has announced overall survival data from its Phase 2 trial of BXCL701 plus Keytruda in patients with small cell neuroendocrine prostate cancer. The data shows a median overall survival of 13.6 months and a 12-month survival rate of 56.5%.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 11:03 am

OCGN

The National Institute of Allergy and Infectious Diseases will conduct a trial comparing the administration of Ocugen's mucosal vaccine candidate, OCU500, via inhalation into the lungs and as nasal spray. The clinical trials are scheduled to start in early 2024. Ocugen is developing this novel anti-viral mucosal vaccine platform initially targeting COVID-19 and influenza.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 10:38 am

CNTG

Centogene N.V. (NASDAQ:CNTG) has expanded its multiomic diagnostic portfolio, MOx, to include transcriptomic analysis. The updated MOx 2.0 combines DNA sequencing, biochemical testing, and RNA sequencing to provide a comprehensive testing capability. Transcriptomics can reveal mutation-specific RNA patterns, differences in gene expression, and responses to environmental or physiological changes.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 10:34 am

MRK

Merck's Phase 3 KEYNOTE-671 trial of Keytruda, a perioperative treatment regimen for resectable stage II, IIIa or IIIb non-small cell lung cancer, has met its dual primary endpoint of overall survival.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 10:34 am

ANNX

Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company, announced that the European Medicines Agency (EMA) has granted orphan drug designation to ANX005 for the treatment of Guillain-Barré Syndrome (GBS). The U.S. Food and Drug Administration (FDA) had previously granted the same designation to ANX005.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 10:31 am

AAPL

GOOG

Google's Pixel 8 Pro, a product of Alphabet Inc., has outperformed Apple Inc.'s iPhone 15 Pro in repeated drop tests, demonstrating superior durability. The Pixel 8 Pro survived the tests with minimal damage, while the iPhone 15 Pro was found to be fragile. Google has also announced that the Pixel 8 and Pixel 8 Pro will receive seven years of Android updates, two years more than Apple's support.

Portfolio Pulse from Rounak Jain

October 10, 2023 | 10:15 am